1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. SWI/SNF Complex

SWI/SNF Complex (SWI/SNF 染色质重塑复合物家族)

SWI/SNF Family of Chromatin-Remodelling Complexes

The SWI/SNF family of chromatin-remodelling complexes, also known as BRG1/BRM-associated factor (BAF) complexes (BOX 1), are key regulators of nucleosome positioning. The SWI/SNF family chromatin remodeling complexes are multi-subunit, ATP-dependent molecular machines that slide and evict nucleosomes. They play a major role in control of the chromatin structure and regulate gene transcription in eukaryotic cells. Mutations of the human complexes are often found in cancers and neurodevelopmental disorders. Mammalian SWI/SNF complexes belong to three broad subfamilies: canonical BAF (cBAF); polybromo-associated BAF (PBAF); and the GLTSCR1 or GLTSCR1L-containing and BRD9-containing (GBAF) complex. All three complexes contain the core subunits including SMARCC1, SMARCC2, and either of the ATPases SMARCA4 or SMARCA2, but also contain numerous variable subunits that provide each of the complexes with a distinct identity.
The human SWI/SNF complexes are frequently mutated in cancer. Loss of the peripheral subunits, such as SMARCB1, PBRM1, and SMARCE1, results in formation of defective complexes, which delocalize on chromatin, deregulate gene transcription, and potentially are oncogenic. Cancer genome-sequencing studies have revealed a remarkably high prevalence of mutations in genes encoding subunits of the SWI/SNF chromatin-remodelling complexes, with nearly 25% of all cancers harbouring aberrations in one or more of these genes. Consequently, increasing research interest is being focused on understanding the prognostic and, in particular, the potential therapeutic implications of mutations in genes encoding SWI/SNF subunits[1][2].

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-128359
    ACBI1 Degrader 99.92%
    ACBI1 是一种有效的,基于 PROTAC 技术的 BAF ATPase 亚基 SMARCA2SMARCA4 降解剂,也是 PBAF 成员 PBRM1 的降解剂, 对 SMARCA2、SMARCA4 和 PBRM1 作用的 DC50 值分别为 6 nM、11 nM 和 32 nM。ACBI1 由一个 bromodomain 配体、linker 和 E3 泛素连接酶 von Hippel-Lindau 构成,能诱导抗增殖作用和凋亡。
    ACBI1
  • HY-44012
    SMARCA-BD ligand 1 for PROTAC Ligand 99.07%
    SMARCA-BD ligand 1 for PROTAC 是一种能够与 BAF ATPase 亚基 SMARCA2 结合的化合物,基于 PROTAC 技术,用于降解 SMARCA2。
    SMARCA-BD ligand 1 for PROTAC
  • HY-44012B
    SMARCA-BD ligand 1 for PROTAC hydrochloride Ligand 99.24%
    SMARCA-BD ligand 1 hydrochloride for PROTAC 是一种能够与 BAF ATPase 亚基 SMARCA2 结合的化合物,基于 PROTAC 技术,用于降解 SMARCA2。
    SMARCA-BD ligand 1 for PROTAC hydrochloride
  • HY-44012A
    SMARCA-BD ligand 1 for PROTAC dihydrochloride Ligand 98.08%
    SMARCA-BD ligand 1 for PROTAC dihydrochloride 是一种能够与 BAF ATPase 亚基 SMARCA2 结合的化合物,基于 PROTAC 技术,使 SMARCA2 降解。
    SMARCA-BD ligand 1 for PROTAC dihydrochloride
  • HY-176872
    SMARCA2 Ligand-Linker Conjugate-4 Inhibitor
    SMARCA2 Ligand-Linker Conjugate-4 是一种靶蛋白配体-连接子偶联物 (Target Protein Ligand-Linker Conjugate),其包含 SMARCA2 配体 (HY-178414) 和 PROTAC 连接子,可募集 E3 连接酶。SMARCA2 Ligand-Linker Conjugate-4 可用于合成 PROTAC SMARCA2 degrader-35 (HY-176871)。
    SMARCA2 Ligand-Linker Conjugate-4
  • HY-176871
    PROTAC SMARCA2 degrader-35 Degrader
    PROTAC SMARCA2 degrader-35 (Compound 43) 是一种选择性 SMARCA2 PROTAC 降解剂,其对 SMARCA2 的 DC50 < 0.1 μM。PROTAC SMARCA2 degrader-35 具有抗癌活性,并通过在 SMARCA4 缺失的癌细胞中阻滞细胞周期和抑制 DNA 复制来调节癌细胞的增殖和生长。粉色:SMARCA2 ligand (HY-178414);蓝色:E3 ligase ligand;黑色:linker
    PROTAC SMARCA2 degrader-35
  • HY-168230
    SMARCA2 ligand-9 Ligand
    SMARCA2 ligand-9 是 SMARCA2 的配体。SMARCA2 ligand-9 可用于合成 PROTAC SMARCA2 degrader-27 (HY-168229)。
    SMARCA2 ligand-9
  • HY-161886
    SMARCA2-IN-7 Inhibitor
    SMARCA2-IN-7 (compound 12),是 BRM 和 BRG1 的双抑制剂 (IC50 均小于 0.005),有抗肿瘤增殖的作用,抑制 BRG1 缺失的 SKMEL5 肿瘤增殖,在 SKMEL5 中的细胞增殖活力为 AAC50 为 13 nM。在 H1299 细胞中抑制 KRT880 的细胞增殖活力为 AAC50 为 42 nM。
    SMARCA2-IN-7
  • HY-144720
    BRG1-IN-1
    BRG1-IN-1 (Compound 11d) 是一种有效的 SMARCA4/BRG1 抑制剂。BRG1-IN-1 在体外使 GBM 细胞对 Temozolomide 的抗增殖和细胞死亡诱导作用敏感方面显示出比 PFI-3 更好的功效。BRG1-IN-1增强 Temozolomide 对皮下 GBM 肿瘤生长的抑制作用。
    BRG1-IN-1
  • HY-169273
    PROTAC SMARCA2 degrader-22 Degrader
    PROTAC SMARCA2 degrader-22 (Compound 5) 是一种 PROTAC 降解剂,用于降解 SMARCA2,在 100 nM 时降解效率为 94%。PROTAC SMARCA2 degrader-22 可抑制细胞 A549 的增殖,EC50 < 250 nM。
    PROTAC SMARCA2 degrader-22
  • HY-168229
    PROTAC SMARCA2 degrader-27 Degrader
    PROTAC SMARCA2 degrader-27 (compound 4) 是一种 PROTAC SMARCA2 降解剂。PROTAC SMARCA2 degrader-27 具有用于研究癌症的潜力 (粉色: SMARCA2 配体 (HY-168230);蓝色: VHL 配体 (HY-168232);黑色: 连接子 (HY-168231))。
    PROTAC SMARCA2 degrader-27
  • HY-170349
    SMARCA2 ligand-11 Ligand
    SMARCA2 ligand-11 是 SMARCA2 的配体,可以作为靶蛋白配体用于合成 PROTAC SMARCA2 degrader-32 (HY-170343)。
    SMARCA2 ligand-11
  • HY-170343
    PROTAC SMARCA2 degrader-32 Degrader
    PROTAC SMARCA2 degrader-32 (Compound 27) 是 SMARCA2 的降解剂,DC50 为 1.3 nM。PROTAC SMARCA2 degrader-32 抑制肺癌细胞 NCI-H838 的增殖,GI50 为 34 nM。(Pink: ligand for target protein SMARCA2 ligand-11 (HY-170349); Black: linker (HY-W895794); Blue: ligand for E3 ligase VHL (HY-170348))
    PROTAC SMARCA2 degrader-32
  • HY-170828
    SMD-1087 Degrader
    SMD-1087 是一种选择性靶向 SMARCA2PROTAC (DC50=8 nM,Dmax=89%),对 SMARCA4 的 DC50>1 μM。SMD-1087 由 E3 连接酶配体 (S,R,S)-AHPC-Me (blue part) (HY-112078),靶蛋白配体 SMI-1074 (red part) (HY-170817),和 PROTAC linker (1r,4r)-tert-Butyl 4-(bromomethyl)cyclohexanecarboxylate (black part) (HY-W890392) 组成。其中,它的 靶蛋白配体+Linker 部分对应 SMARCA2 Ligand-Linker Conjugate-1 (HY-170829)。
    SMD-1087
  • HY-169275
    PROTAC SMARCA2 degrader-24 Degrader
    PROTAC SMARCA2 degrader-24 (Compound 34) 是 SMARCA2 PROTAC 降解剂,在 HeLa 细胞中的DC50 < 0.1 µM。PROTAC SMARCA2 degrader-24 在 HeLa 细胞中降解 SMARCA4DC50 > 10 μM。
    PROTAC SMARCA2 degrader-24
  • HY-170826
    SMARCA2 ligand-14 Ligand
    SMARCA2 ligand-14 是 SMARCA2 的配体,可以用于合成 PROTAC 降解剂 SMD-3236 (HY-170824)。
    SMARCA2 ligand-14
  • HY-134920
    LW106
    LW106 是一种选择性 IDO1 抑制剂,IC50 为 1.57 μM。LW106 对 IDO2 和 TDO 无抑制作用。LW106 通过限制基质免疫串扰和肿瘤微环境中的肿瘤干细胞 (CSC) 富集来抑制肿瘤生长。LW106 可减少异种移植肿瘤中的肿瘤干细胞 (CSC) 亚群,导致肿瘤细胞增殖/侵袭性降低,并诱导肿瘤细胞凋亡 (apoptosis)。LW106 可用于肺癌和黑色素瘤的研究。
    LW106

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.